Ricardo Almiron
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Ricardo Almiron has a total of 47 co-authors. Here are the top co-authors by number of shared publications:
- Asha Jose
Department of Medicine, Renal Section, Boston University Chobanian & Avedisian School of Medicine, Boston, MA
3 shared publications - Saran Lotfollahzadeh
Renal Section, Department of Medicine, Boston University School of Medicine, Boston, Massachusetts
3 shared publications - Vipul Chimanlal Chitalia
Renal Section, Department of Medicine, Boston University Chobanian & Avedisian School of Medicine, Boston, MA 02118, USA
3 shared publications - Isaac Sellinger
Renal Section, Department of Medicine, Boston Medical Center, Boston University Chobanian and Avedisian School of Medicine, Boston, Massachusetts
2 shared publications - Wenqing Yin
Renal Section, Department of Medicine, Boston University School of Medicine, Boston, Massachusetts
2 shared publications - Abbas Brahim Malloum
Renal Section, Department of Medicine, Boston Medical Center, Boston University Chobanian and Avedisian School of Medicine, Boston, Massachusetts
1 shared publication
Latest Publications
- 21 August 2026
- Published by Wolters Kluwer Health in Journal of the American Society of Nephrology
Indoxyl Sulfate Promotes Uremic Arterial and Venous Thrombosis by Stabilizing Indoleamine 2,3-Dioxygenase 1 via the E3 Ligase Split-Hand/Foot Malformation 3
Key Points: Indoleamine 2,3-dioxygenase 1 is a central regulator of tryptophan metabolism and contributed to CKD-associated thromboinflammation and endothelial dysfunction. Indoxyl sulfate, a protein-bound uremic toxin, stabilized indoleamine 2,3-dioxygenase 1 by partially inhibiting its interaction with split-hand/foot malformation 3 and reducing ubiquitination. Targeting indoleamine 2,3-dioxygenase 1 degradation by modulating split-hand/foot malformation 3 may offer a novel therapeutic approach to mitigate CKD-associated arterial and venous thrombosis. Background: The uremic milieu of CKD is characterized by the accumulation of protein-bound uremic toxins, which contribute to thrombosis. Indoxyl sulfate, a bona fide uremic toxin, upregulates indoleamine 2,3-dioxygenase 1 (IDO1), thereby augmenting kynurenine biogenesis. Both toxins activate tissue factor and thrombosis. Despite this pathogenic synergy, the mechanisms of indoxyl sulfate–mediated IDO1 stabilization remain undefined. Methods: We employed targeted metabolomics, super-resolution microscopy, and gain- and loss-of-function experiments using nanoparticle-mediated gene delivery in mice to modulate split-hand/foot malformation 3 (SHFM3) expression. This was followed by carotid artery or inferior vena cava thrombosis assays in indoxyl sulfate–fed and adenine-induced CKD models. Results: Among several F-box–containing E3 ligases, SHFM3 downregulated IDO1 in endothelial cells. SHFM3 constitutively interacted with IDO1, which is partially disrupted by indoxyl sulfate–induced nuclear sequestration of SHFM3 at concentrations corresponding to early-to-advanced CKD. SHFM3 interacted with the N-terminus of IDO1, ubiquitinated, and destabilized it. Indoxyl sulfate upregulated IDO1 activity, thereby increasing kynurenine biogenesis in N-terminus– and SHFM3-dependent manners. In an indoxyl sulfate–fed mouse model, endothelial cell–specific SHFM3 knockdown increased IDO1 and tissue factor while accelerating arterial thrombosis, and these effects were reversed by endothelial cell–specific SHFM3 overexpression. CKD mice exhibited 55% higher venous thrombogenicity than controls. Endothelial cell–specific SHFM3 overexpression significantly reversed these effects in control mice and, to a lesser extent, in CKD mice. Serum indoxyl sulfate levels significantly correlated with the global IDO1 activity and venous clot weights. Conclusions: SHFM3 functions as an indoxyl sulfate–sensitive potent E3 ligase of IDO1, targeting it for degradation, even with partial interaction with IDO1 in the uremic milieu. This work also described a CKD-induced venous thrombosis model and supports the selective rewiring of uremic toxins in post-translational proteostasis, amplifying indoxyl sulfate–mediated arterial and venous thrombosis.
- 21 August 2026
- Published by Wolters Kluwer Health in Journal of the American Society of Nephrology
Indoxyl Sulfate Promotes Uremic Arterial and Venous Thrombosis by Stabilizing Indoleamine 2,3-Dioxygenase 1 via the E3 Ligase Split-Hand/Foot Malformation 3
Key Points: Indoleamine 2,3-dioxygenase 1 is a central regulator of tryptophan metabolism and contributed to CKD-associated thromboinflammation and endothelial dysfunction. Indoxyl sulfate, a protein-bound uremic toxin, stabilized indoleamine 2,3-dioxygenase 1 by partially inhibiting its interaction with split-hand/foot malformation 3 and reducing ubiquitination. Targeting indoleamine 2,3-dioxygenase 1 degradation by modulating split-hand/foot malformation 3 may offer a novel therapeutic approach to mitigate CKD-associated arterial and venous thrombosis. Background: The uremic milieu of CKD is characterized by the accumulation of protein-bound uremic toxins, which contribute to thrombosis. Indoxyl sulfate, a bona fide uremic toxin, upregulates indoleamine 2,3-dioxygenase 1 (IDO1), thereby augmenting kynurenine biogenesis. Both toxins activate tissue factor and thrombosis. Despite this pathogenic synergy, the mechanisms of indoxyl sulfate–mediated IDO1 stabilization remain undefined. Methods: We employed targeted metabolomics, super-resolution microscopy, and gain- and loss-of-function experiments using nanoparticle-mediated gene delivery in mice to modulate split-hand/foot malformation 3 (SHFM3) expression. This was followed by carotid artery or inferior vena cava thrombosis assays in indoxyl sulfate–fed and adenine-induced CKD models. Results: Among several F-box–containing E3 ligases, SHFM3 downregulated IDO1 in endothelial cells. SHFM3 constitutively interacted with IDO1, which is partially disrupted by indoxyl sulfate–induced nuclear sequestration of SHFM3 at concentrations corresponding to early-to-advanced CKD. SHFM3 interacted with the N-terminus of IDO1, ubiquitinated, and destabilized it. Indoxyl sulfate upregulated IDO1 activity, thereby increasing kynurenine biogenesis in N-terminus– and SHFM3-dependent manners. In an indoxyl sulfate–fed mouse model, endothelial cell–specific SHFM3 knockdown increased IDO1 and tissue factor while accelerating arterial thrombosis, and these effects were reversed by endothelial cell–specific SHFM3 overexpression. CKD mice exhibited 55% higher venous thrombogenicity than controls. Endothelial cell–specific SHFM3 overexpression significantly reversed these effects in control mice and, to a lesser extent, in CKD mice. Serum indoxyl sulfate levels significantly correlated with the global IDO1 activity and venous clot weights. Conclusions: SHFM3 functions as an indoxyl sulfate–sensitive potent E3 ligase of IDO1, targeting it for degradation, even with partial interaction with IDO1 in the uremic milieu. This work also described a CKD-induced venous thrombosis model and supports the selective rewiring of uremic toxins in post-translational proteostasis, amplifying indoxyl sulfate–mediated arterial and venous thrombosis.
- Open Access
- 13 October 2025
- Published by Wolters Kluwer Health in Kidney360
- Vol. 7 (2) , 233-246
A Murine Model of Cardiovascular-Kidney-Metabolic Syndrome Demonstrates Compromised Limb Function in the Ischemic Hind Limb
Key Points: Cardiovascular-kidney-metabolic (CKM) is a global public health problem; however, its mediators remain poorly known, in part due to the lack of a reliable animal model. A combination of high fat and adenine diet recapitulate some of the CKD and metabolic phenotypes of CKM. This model also demonstrates myocardial fibrosis and peripheral artery disease with sex-based differences and can be leveraged to probe mechanisms of CKM. Background: Cardiovascular-kidney-metabolic (CKM) syndrome is a public health problem in the United States and results in premature cardiovascular disease at a relatively preserved GFR. The molecular mediators of CKM are poorly understood, partly due to the lack of a reliable animal model. We set out to generate an animal model with renal and metabolic dysfunctions, using peripheral artery disease (PAD) as a CKM manifestation. Methods: C57BL/6 male and female mice were randomized into four groups: a normal diet (controls), a 0.2% adenine diet (AD, a CKD model), a high-fat diet (HFD, a metabolic model), and a combination of HFD+AD (a potential CKM model). The mice underwent a hind limb ischemia, followed by an array of structural, endurance, and postexercise hyperemia assays. Results: Compared with control mice, HFD+AD male mice had 23%–50% higher weight and GFR than the AD group ( P = 0.003). The kidneys of HFD+AD showed tubular atrophy, tubulointerstitial fibrosis, immune infiltration, glomerulomegaly, consistent with glomerular hyperperfusion, hypercholesterolemia, impaired glucose tolerance, and adipophilin in the liver, an early marker of hepatic steatosis, and myocardial fibrosis. The HFD+AD mice showed reductions in the hind limb perfusion ratios, microcapillary density, type 2 muscle fibers, and increased muscle fibrosis, immune infiltration, and lowest cross-sectional muscle area. Female CKM mice revealed distinct differences from male mice. Compared with AD and HFD alone, female CKM mice exposed to HFD+AD demonstrated additive phenotypes in endurance assays (distance traveled, exhaustion time, and grip strength) without a similar effect in postischemia perfusion, suggesting skeletal muscle, and microcapillary dysfunction. Conclusions: A combination of HFD+AD in mice displays features of CKD, metabolic disorders, and cardiovascular disease at a higher GFR, consistent with human CKM. This model can be explored to probe the mechanisms and heterogeneity and sex-specific differences in CKM.
- 13 October 2025
- Published by Wolters Kluwer Health in Kidney360
- Vol. 7 (2) , 233-246
Open AccessA Murine Model of Cardiovascular-Kidney-Metabolic Syndrome Demonstrates Compromised Limb Function in the Ischemic Hind Limb
Key Points: Cardiovascular-kidney-metabolic (CKM) is a global public health problem; however, its mediators remain poorly known, in part due to the lack of a reliable animal model. A combination of high fat and adenine diet recapitulate some of the CKD and metabolic phenotypes of CKM. This model also demonstrates myocardial fibrosis and peripheral artery disease with sex-based differences and can be leveraged to probe mechanisms of CKM. Background: Cardiovascular-kidney-metabolic (CKM) syndrome is a public health problem in the United States and results in premature cardiovascular disease at a relatively preserved GFR. The molecular mediators of CKM are poorly understood, partly due to the lack of a reliable animal model. We set out to generate an animal model with renal and metabolic dysfunctions, using peripheral artery disease (PAD) as a CKM manifestation. Methods: C57BL/6 male and female mice were randomized into four groups: a normal diet (controls), a 0.2% adenine diet (AD, a CKD model), a high-fat diet (HFD, a metabolic model), and a combination of HFD+AD (a potential CKM model). The mice underwent a hind limb ischemia, followed by an array of structural, endurance, and postexercise hyperemia assays. Results: Compared with control mice, HFD+AD male mice had 23%–50% higher weight and GFR than the AD group ( P = 0.003). The kidneys of HFD+AD showed tubular atrophy, tubulointerstitial fibrosis, immune infiltration, glomerulomegaly, consistent with glomerular hyperperfusion, hypercholesterolemia, impaired glucose tolerance, and adipophilin in the liver, an early marker of hepatic steatosis, and myocardial fibrosis. The HFD+AD mice showed reductions in the hind limb perfusion ratios, microcapillary density, type 2 muscle fibers, and increased muscle fibrosis, immune infiltration, and lowest cross-sectional muscle area. Female CKM mice revealed distinct differences from male mice. Compared with AD and HFD alone, female CKM mice exposed to HFD+AD demonstrated additive phenotypes in endurance assays (distance traveled, exhaustion time, and grip strength) without a similar effect in postischemia perfusion, suggesting skeletal muscle, and microcapillary dysfunction. Conclusions: A combination of HFD+AD in mice displays features of CKD, metabolic disorders, and cardiovascular disease at a higher GFR, consistent with human CKM. This model can be explored to probe the mechanisms and heterogeneity and sex-specific differences in CKM.
- 23 April 2025
- Published by American Association for the Advancement of Science (AAAS) in Science Translational Medicine
- Vol. 17 (795) , eadn5772
Activation and targetability of TYMP–IL-6–TF signaling in the skin microenvironment in uremic calciphylaxis
Calciphylaxis is an orphan disease characterized by dermal microvessel thrombosis, inflicting painful cutaneous necrosis. It occurs predominantly in patients with end-stage kidney disease and has high mortality, elusive pathogenesis, and no approved therapies. We demonstrate that sera from patients with calciphylaxis induced de novo synthesis of interleukin-6 (IL-6) and soluble IL-6 receptor (IL-6R) and stimulated Janus kinase-2 (JAK) and signal transducer and activator of transcription (STAT)–3 phosphorylation in primary human dermal microvascular endothelial cells (ECs). Calciphylaxis skin demonstrated an altered microenvironment characterized by a gain of proximal and distal IL-6 ligand-receptor interactions. Microvessels are the predominant senders and recipients of IL-6 signaling, which, along with up-regulated A disintegrin and metalloproteinase 17 in dermal vasculature and interstitial IL-6R, supported trans–IL-6 signaling in calciphylaxis lesions. Calciphylaxis serum up-regulated thymidine phosphorylase (TYMP) in ECs. TYMP up-regulated IL-6, which activated tissue factor (TF), a primary trigger of the extrinsic coagulation cascade. IL-6–TF signaling in ECs was partially triggered by elevated IL-6 and kynurenine amounts in calciphylaxis serum and was inhibited by anti–IL-6 treatment. The TF-inducing ability of calciphylaxis serum is correlated with disease activity and response to IL-6 inhibitors in ECs. Calciphylaxis is therefore a combination of serum-inducing TYMP–IL-6–TF signaling in ECs and a heterogeneous permissive local dermal microenvironment. The latter is characterized by microvessels initiating IL-6 signaling and multiway cross-talk with adipocytes and eccrine glands, perpetuating the sinister thrombotic milieu. Our results support exploring the IL-6–TF–inducing ability of calciphylaxis serum as an activity marker and IL-6 as a therapeutic target for uremic calciphylaxis.
- 23 April 2025
- Published by American Association for the Advancement of Science (AAAS) in Science Translational Medicine
- Vol. 17 (795) , eadn5772
Activation and targetability of TYMP–IL-6–TF signaling in the skin microenvironment in uremic calciphylaxis
Calciphylaxis is an orphan disease characterized by dermal microvessel thrombosis, inflicting painful cutaneous necrosis. It occurs predominantly in patients with end-stage kidney disease and has high mortality, elusive pathogenesis, and no approved therapies. We demonstrate that sera from patients with calciphylaxis induced de novo synthesis of interleukin-6 (IL-6) and soluble IL-6 receptor (IL-6R) and stimulated Janus kinase-2 (JAK) and signal transducer and activator of transcription (STAT)–3 phosphorylation in primary human dermal microvascular endothelial cells (ECs). Calciphylaxis skin demonstrated an altered microenvironment characterized by a gain of proximal and distal IL-6 ligand-receptor interactions. Microvessels are the predominant senders and recipients of IL-6 signaling, which, along with up-regulated A disintegrin and metalloproteinase 17 in dermal vasculature and interstitial IL-6R, supported trans–IL-6 signaling in calciphylaxis lesions. Calciphylaxis serum up-regulated thymidine phosphorylase (TYMP) in ECs. TYMP up-regulated IL-6, which activated tissue factor (TF), a primary trigger of the extrinsic coagulation cascade. IL-6–TF signaling in ECs was partially triggered by elevated IL-6 and kynurenine amounts in calciphylaxis serum and was inhibited by anti–IL-6 treatment. The TF-inducing ability of calciphylaxis serum is correlated with disease activity and response to IL-6 inhibitors in ECs. Calciphylaxis is therefore a combination of serum-inducing TYMP–IL-6–TF signaling in ECs and a heterogeneous permissive local dermal microenvironment. The latter is characterized by microvessels initiating IL-6 signaling and multiway cross-talk with adipocytes and eccrine glands, perpetuating the sinister thrombotic milieu. Our results support exploring the IL-6–TF–inducing ability of calciphylaxis serum as an activity marker and IL-6 as a therapeutic target for uremic calciphylaxis.